Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Get Free Trial
Send Info
Recommendations
Silverback Therapeutics price target lowered to $5 from $6 at Stifel » 14:38
05/13/22
05/13
14:38
05/13/22
14:38
SBTX

Silverback Therapeutics

$2.97 /

-0.055 (-1.82%)

Stifel analyst Stephen…

Stifel analyst Stephen Willey lowered the firm's price target on Silverback Therapeutics to $5 from $6 and keeps a Hold rating on the shares. The focus has shifted "squarely" to the prospects of SBT8230 following Silverback's discontinuation of its two lead oncology assets, said Willey, who thinks the extended timelines before there is more clarity is likely to keep shares in check despite what he notes is a current "sub-cash valuation."

ShowHide Related Items >><<
SBTX Silverback Therapeutics
$2.97 /

-0.055 (-1.82%)

04/01/22 Goldman Sachs
Silverback Therapeutics downgraded to Neutral from Buy at Goldman Sachs
04/01/22 SVB Leerink
Silverback Therapeutics downgraded to Market Perform from Outperform at SVB Leerink
04/01/22 JonesTrading
Silverback Therapeutics downgraded to Hold from Buy at JonesTrading
04/01/22 SVB Leerink
Silverback Therapeutics downgraded to Market Perform from Outperform at SVB Leerink
SBTX Silverback Therapeutics
$2.97 /

-0.055 (-1.82%)

05/12/22
Silverback Therapeutics reports Q1 EPS (70c), consensus (54c)
03/31/22
Silverback Therapeutics reports FY21 EPS ($2.56), consensus ($2.60)
SBTX Silverback Therapeutics
$2.97 /

-0.055 (-1.82%)

04/01/22
Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
06/10/22
Silverback Therapeutics, Inc.
Earnings
Silverback Therapeutics reports Q1 EPS (70c), consensus (54c) » 16:06
05/12/22
05/12
16:06
05/12/22
16:06
SBTX

Silverback Therapeutics

$2.98 /

+0.08 (+2.76%)

"In the first…

"In the first quarter of 2022, we have made significant progress in advancing the preclinical development of SBT8230, a first-in-class antibody-drug conjugate that we believe has the potential to drive functional cure in patients with chronic hepatitis B (cHBV) by eliciting a liver-localized anti-viral response," said Laura Shawver, Ph.D., CEO. "We believe that activating the immune response is an important component of a functional cure and may be combined with treatments that target the HBV life cycle to improve durability. Our team is on track to complete a regulatory submission in the fourth quarter of 2022, enabling the planned initiation of the single ascending dose healthy volunteer cohort of the Phase 1 study in the first quarter of 2023. We plan to report data from this cohort in the second half of 2023."

ShowHide Related Items >><<
SBTX Silverback Therapeutics
$2.98 /

+0.08 (+2.76%)

04/01/22 Goldman Sachs
Silverback Therapeutics downgraded to Neutral from Buy at Goldman Sachs
04/01/22 SVB Leerink
Silverback Therapeutics downgraded to Market Perform from Outperform at SVB Leerink
04/01/22 JonesTrading
Silverback Therapeutics downgraded to Hold from Buy at JonesTrading
04/01/22 SVB Leerink
Silverback Therapeutics downgraded to Market Perform from Outperform at SVB Leerink
SBTX Silverback Therapeutics
$2.98 /

+0.08 (+2.76%)

03/31/22
Silverback Therapeutics reports FY21 EPS ($2.56), consensus ($2.60)
SBTX Silverback Therapeutics
$2.98 /

+0.08 (+2.76%)

04/01/22
Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
06/10/22
Silverback Therapeutics, Inc.
Over a month ago
Downgrade
Silverback Therapeutics downgraded to Neutral from Buy at Goldman Sachs » 16:44
04/01/22
04/01
16:44
04/01/22
16:44
SBTX

Silverback Therapeutics

$3.22 /

-0.22 (-6.40%)

Goldman Sachs analyst…

Goldman Sachs analyst Paul Choi downgraded Silverback Therapeutics to Neutral from Buy with a price target of $3.50, down from $25. Silverback reported Q4 earnings, and announced a major strategic change as the company has decided to discontinue its oncology programs, SBT6050 and SBT6290, "both of which represented the most advanced assets in the pipeline."

ShowHide Related Items >><<
SBTX Silverback Therapeutics
$3.22 /

-0.22 (-6.40%)

04/01/22 SVB Leerink
Silverback Therapeutics downgraded to Market Perform from Outperform at SVB Leerink
04/01/22 JonesTrading
Silverback Therapeutics downgraded to Hold from Buy at JonesTrading
04/01/22 SVB Leerink
Silverback Therapeutics downgraded to Market Perform from Outperform at SVB Leerink
04/01/22 H.C. Wainwright
Silverback Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
SBTX Silverback Therapeutics
$3.22 /

-0.22 (-6.40%)

03/31/22
Silverback Therapeutics reports FY21 EPS ($2.56), consensus ($2.60)
11/10/21
Silverback Therapeutics reports Q3 EPS (65c), consensus (67c)
SBTX Silverback Therapeutics
$3.22 /

-0.22 (-6.40%)

04/01/22
Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
On The Fly
Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations » 09:34
04/01/22
04/01
09:34
04/01/22
09:34
WYNN

Wynn Resorts

$79.77 /

-1.34 (-1.65%)

, DELL

Dell Technologies

$50.18 /

-4.1 (-7.55%)

, IMRX

Immuneering

$6.47 /

-0.36 (-5.27%)

, POSH

Poshmark

$12.65 /

-0.69 (-5.17%)

, VRT

Vertiv Holdings

$14.00 /

+0.28 (+2.04%)

, BLND

Blend Labs

$5.68 /

-0.3 (-5.02%)

, UPST

Upstart

$109.00 /

-4.87 (-4.28%)

, GPS

Gap

$14.08 /

-0.56 (-3.83%)

, TELL

Tellurian

$5.30 /

-0.14 (-2.57%)

, CMA

Comerica

$90.42 /

-2.455 (-2.64%)

, CHKP

Check Point

$138.42 /

+0.04 (+0.03%)

, PARA

Paramount

$37.80 /

-0.315 (-0.83%)

, AWKNF

Awakn Life Sciences

$1.20 /

+ (+0.00%)

, SBTX

Silverback Therapeutics

$3.46 /

-0.065 (-1.85%)

, W

Wayfair

$110.75 /

-10.75 (-8.85%)

Institutional investors…

Open Full Text

ShowHide Related Items >><<
WYNN Wynn Resorts
$79.77 /

-1.34 (-1.65%)

04/01/22
Macau reports March casino revenue down 55.8% to 3.67B patacas
03/30/22
Nevada reports February statewide gaming win up 44.1% to $1.11B
03/17/22
New Jersey reports February gaming revenue up 29.5% to $373.3M
03/01/22
Macau reports February casino revenue up 6.1% to 7.76B patacas
W Wayfair
$110.75 /

-10.75 (-8.85%)

02/24/22
Wayfair trading resumes
02/24/22
Wayfair trading halted, volatility trading pause
02/24/22
Wayfair sees Q1 CapEx $95M-$105M
02/24/22
Wayfair expects FY to be 'modestly profitable' on adjusted EBITDA basis
VRT Vertiv Holdings
$14.00 /

+0.28 (+2.04%)

03/11/22
Vertiv, Elea Digital enter strategic alliance for edge data center services
02/23/22
Vertiv Holdings falls -39.9%
02/23/22
Vertiv Holdings falls -38.4%
02/23/22
Vertiv Holdings falls -40.0%
UPST Upstart
$109.00 /

-4.87 (-4.28%)

03/10/22
Volkswagen selects Upstart Auto Retail as a preferred digital retail provider
03/08/22
Sandbox Banking announces alliance partnership with Upstart
02/15/22
Upstart announces $400M share repurchase program
02/14/22
Third Point buys Rivian, exits Meta in Q4
TELL Tellurian
$5.30 /

-0.14 (-2.57%)

02/14/22
Paulson buys Cerner, exits Pretium in Q4
10/22/21
Tellurian to transfer listing of common stock to NYSE American from Nasdaq
POSH Poshmark
$12.65 /

-0.69 (-5.17%)

03/28/22
Poshmark director sells $2.66M in common stock
03/22/22
Poshmark falls 6% to $13.00 after Q4 earnings miss and below-consensus guidance
11/16/21
Poshmark appoints Rodrigo Brumana as CFO
11/09/21
Poshmark drops 26% after Q3 report and quarterly guidance
PARA Paramount
$37.80 /

-0.315 (-0.83%)

03/17/22
Avid enters into agreement with Paramound for managed cloud solutions
02/28/22
Discovery confirms plans to appoint Chris Licht to lead CNN
02/16/22
Paramount raising global streaming subscriber goal to more than 100M by end 2024
02/16/22
ViacomCBS to change name to Paramount, Class B ticker to 'PARA'
IMRX Immuneering
$6.47 /

-0.36 (-5.27%)

12/06/21
Immuneering Corporation (Class A Stock) trading resumes
12/06/21
Immuneering Corporation (Class A Stock) trading halted, volatility trading pause
GPS Gap
$14.08 /

-0.56 (-3.83%)

03/10/22
Gap says suspended deliveries to Russia
03/04/22
Gap rises 11.0%
03/03/22
Gap up 16% after Q4 results, FY22 guidance
02/24/22
Gap raises quarterly dividend 25% to 60c per share
DELL Dell Technologies
$50.18 /

-4.1 (-7.55%)

02/24/22
Dell Technologies initiates quarterly dividend of 33c per share
02/14/22
Elliott buys Switch, exits Public Storage in Q4
01/02/22
Fly Intel: Top five weekend stock stories
11/23/21
HP Enterprise, Dell, IBM and others to compete for orders on $1.6B Army contract
CHKP Check Point
$138.42 /

+0.04 (+0.03%)

03/02/22
Check Point launches unified go-to-market organization
02/01/22
Check Point acquires Spectral, terms not disclosed
01/17/22
Check Point report shows DHL most imitated brand in phishing attempts in Q4
10/28/21
Check Point sees 'very healthy' Q4
BLND Blend Labs
$5.68 /

-0.3 (-5.02%)

03/21/22
Blend Labs falls -9.1%
03/08/22
Blend Labs falls -11.3%
11/15/21
Tiger Global boosts stake in Snowflake, exits TAL Education Group
11/11/21
Blend Labs falls -16.7%
WYNN Wynn Resorts
$79.77 /

-1.34 (-1.65%)

04/01/22 Citi
Wynn Resorts upgraded to Buy from Neutral at Citi
03/23/22 Craig-Hallum
Gan Limited price target lowered to $8 from $14 at Craig-Hallum
03/07/22 Argus
DraftKings cut to Hold at Argus on growing Wynn and MGM competition
02/16/22 CBRE
Wynn Resorts price target raised to $130 from $125 at CBRE
DELL Dell Technologies
$50.18 /

-4.1 (-7.55%)

04/01/22 Goldman Sachs
Dell Technologies downgraded to Neutral from Conviction Buy at Goldman Sachs
03/31/22 Barclays
Dell Technologies price target lowered to $53 from $54 at Barclays
03/31/22 Morgan Stanley
Dell Technologies downgraded to Equal Weight from Overweight at Morgan Stanley
03/08/22 Evercore ISI
Dell Technologies upgraded to Outperform from In Line at Evercore ISI
IMRX Immuneering
$6.47 /

-0.36 (-5.27%)

03/31/22 Oppenheimer
Immuneering initiated with an Outperform at Oppenheimer
01/07/22 Piper Sandler
Immuneering initiated with an Overweight at Piper Sandler
01/03/22 Guggenheim
Immuneering price target lowered to $30 from $42 at Guggenheim
08/24/21 Morgan Stanley
Immuneering initiated with an Equal Weight at Morgan Stanley
POSH Poshmark
$12.65 /

-0.69 (-5.17%)

03/31/22 Stifel
Poshmark downgraded to Hold from Buy at Stifel
03/23/22 Wedbush
Poshmark price target lowered to $16 from $23 at Wedbush
03/23/22 MKM Partners
Poshmark price target raised to $12 from $10 at MKM Partners
03/23/22 Stifel
Poshmark price target lowered to $19 from $23 at Stifel
VRT Vertiv Holdings
$14.00 /

+0.28 (+2.04%)

04/01/22 JPMorgan
Vertiv upgraded to Overweight on 'compelling' risk/reward at JPMorgan
04/01/22 JPMorgan
Vertiv Holdings upgraded to Overweight from Neutral at JPMorgan
03/31/22 Citi
Vertiv positioned for significantly improved profitability, says Citi
02/24/22 Cowen
Cowen downgrades Vertiv after 'dismal' Q4 performance
BLND Blend Labs
$5.68 /

-0.3 (-5.02%)

04/01/22 Truist
Blend Labs price target lowered to $5.50 from $7.50 at Truist
04/01/22 Canaccord
Canaccord downgrades Blend Labs to Hold, cuts target to $5 from $28
04/01/22 Wells Fargo
Blend Labs downgraded to Equal Weight from Overweight at Wells Fargo
04/01/22 KeyBanc
Blend Labs price target lowered to $6 from $10 at KeyBanc
UPST Upstart
$109.00 /

-4.87 (-4.28%)

03/31/22 Stephens
Stephens 'cautious' on Upstart, starts at Equal Weight
03/31/22 Stephens
Upstart initiated with an Equal Weight at Stephens
03/22/22 Wedbush
Wedbush downgrades Upstart to Underperform, lowers price target to $75
03/22/22 Wedbush
Upstart downgraded to Underperform from Neutral at Wedbush
GPS Gap
$14.08 /

-0.56 (-3.83%)

04/01/22 Barclays
Gap downgraded to sell on heightened risks at Barclays
04/01/22 Barclays
Gap downgraded to Underweight from Equal Weight at Barclays
03/09/22 Daiwa
Gap downgraded to Underperform from Neutral at Daiwa
03/04/22 BMO Capital
Gap price target lowered to $16 from $19 at BMO Capital
TELL Tellurian
$5.30 /

-0.14 (-2.57%)

04/01/22 Credit Suisse
Tellurian upgraded to Outperform from Neutral at Credit Suisse
07/08/21 B. Riley
B. Riley starts Tellurian with Buy on liquefied natural gas growth
07/08/21 B. Riley
Tellurian initiated with a Buy at B. Riley
06/22/21 Roth Capital
Tellurian pipeline could lead to reduced emissions, says Roth Capital
CMA Comerica
$90.42 /

-2.455 (-2.64%)

04/01/22 JPMorgan
Comerica upgraded to Overweight on tailwind from hikes at JPMorgan
04/01/22 Goldman Sachs
Comerica upgraded to Neutral from Sell at Goldman Sachs
04/01/22 JPMorgan
Comerica upgraded to Overweight from Neutral at JPMorgan
03/24/22 Citi
Comerica assumed with a Buy at Citi
CHKP Check Point
$138.42 /

+0.04 (+0.03%)

03/31/22 Summit Insights
Summit Insights starts Check Point at Buy, sees it as 'solid defensive stock'
03/31/22 Summit Insights
Check Point initiated with a Buy at Summit Insights
03/21/22 Piper Sandler
Check Point downgraded to Underweight from Neutral at Piper Sandler
03/17/22 Deutsche Bank
Check Point price target raised to $160 from $154 at Deutsche Bank
PARA Paramount
$37.80 /

-0.315 (-0.83%)

04/01/22 JPMorgan
Paramount reinstated with a Neutral at JPMorgan
03/18/22 UBS
Paramount price target lowered to $29 from $33 at UBS
02/17/22 Barrington
Paramount price target lowered to $34 from $50 at Barrington
AWKNF Awakn Life Sciences
$1.20 /

+ (+0.00%)

04/01/22 Stifel
Awakn Life Sciences initiated with a Speculative Buy at Stifel
02/01/22 H.C. Wainwright
Awakn Life Sciences initiated with a Buy at H.C. Wainwright
SBTX Silverback Therapeutics
$3.46 /

-0.065 (-1.85%)

04/01/22 SVB Leerink
Silverback Therapeutics downgraded to Market Perform from Outperform at SVB Leerink
04/01/22 JonesTrading
Silverback Therapeutics downgraded to Hold from Buy at JonesTrading
04/01/22 SVB Leerink
Silverback Therapeutics downgraded to Market Perform from Outperform at SVB Leerink
04/01/22 H.C. Wainwright
Silverback Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
W Wayfair
$110.75 /

-10.75 (-8.85%)

04/01/22 Needham
Wayfair price target lowered to $150 from $180 at Needham
04/01/22 Barclays
Wayfair downgraded to sell on heightened risks at Barclays
04/01/22 Barclays
Wayfair downgraded to Underweight from Equal Weight at Barclays
03/30/22 Loop Capital
Loop Capital cuts Wayfair to Sell on inflation, rising rate headwinds
WYNN Wynn Resorts
$79.77 /

-1.34 (-1.65%)

02/15/22
Wynn Resorts reports Q4 EPS ($1.54), consensus ($1.25)
02/15/22
Notable companies reporting after market close
11/09/21
Wynn Resorts reports Q3 adjusted EPS ($1.24), consensus ($1.31)
11/09/21
Notable companies reporting after market close
W Wayfair
$110.75 /

-10.75 (-8.85%)

02/24/22
Wayfair reports Q4 EPS (92c), consensus (69c)
02/23/22
Notable companies reporting before tomorrow's open
11/04/21
Wayfair reports Q3 EPS 14c, consensus 0c
VRT Vertiv Holdings
$14.00 /

+0.28 (+2.04%)

02/23/22
Vertiv Holdings sees 2022 adjusted EPS 65c-75c, consensus $1.33
02/23/22
Vertiv Holdings sees Q1 adjusted EPS (20c)-(15c), consensus 23c
02/23/22
Vertiv Holdings reports Q4 EPS 6c, consensus 28c
10/27/21
Vertiv Holdings raises FY21 adjusted EPS view to 97c-$1.03 from 96c-$1.01
UPST Upstart
$109.00 /

-4.87 (-4.28%)

02/16/22
Upstart sees FY22 revenue $1.4B, consensus $1.21B
02/16/22
Upstart sees Q1 revenue $295M-$305M, consensus $258.3M
02/16/22
Upstart reports Q4 EPS 89c, consensus 51c
TELL Tellurian
$5.30 /

-0.14 (-2.57%)

02/23/22
Tellurian ended FY21 with approximately $305.5M in cash
11/03/21
Tellurian reports Q3 EPS (4c), consensus (4c)
SBTX Silverback Therapeutics
$3.46 /

-0.065 (-1.85%)

03/31/22
Silverback Therapeutics reports FY21 EPS ($2.56), consensus ($2.60)
11/10/21
Silverback Therapeutics reports Q3 EPS (65c), consensus (67c)
POSH Poshmark
$12.65 /

-0.69 (-5.17%)

03/22/22
Poshmark sees Q1 revenue $86M-$88M, consensus $90.53M
03/22/22
Poshmark reports Q4 EPS (19c), consensus (18c)
03/22/22
Notable companies reporting after market close
11/09/21
Poshmark reports Q3 EPS (9c), consensus (7c)
IMRX Immuneering
$6.47 /

-0.36 (-5.27%)

03/10/22
Immuneering reports Q4 EPS (42c), consensus (39c)
11/09/21
Immuneering reports Q3 EPS (47c), consensus (57c)
GPS Gap
$14.08 /

-0.56 (-3.83%)

03/03/22
Gap sees FY22 adjusted EPS $1.85-$2.05, consensus $1.86
03/03/22
Gap reports Q4 adjusted EPS (2c), consensus (14c)
03/03/22
Notable companies reporting after market close
11/23/21
Gap reports Q3 Old Navy SSS down 9% y/y
DELL Dell Technologies
$50.18 /

-4.1 (-7.55%)

02/24/22
Dell Technologies reports Q4 adjusted EPS $1.72, consensus $1.95
02/24/22
Notable companies reporting after market close
11/23/21
Dell Technologies reports Q3 adjusted EPS $2.37, consensus $2.18
11/23/21
Notable companies reporting after market close
CMA Comerica
$90.42 /

-2.455 (-2.64%)

01/19/22
Comerica reports Q4 EPS $1.66, consensus $1.58
10/20/21
Comerica reports Q3 EPS $1.90, consensus $1.64
CHKP Check Point
$138.42 /

+0.04 (+0.03%)

02/03/22
Check Point sees FY22 EPS $6.90-$7.50, consensus $7.34
02/03/22
Check Point sees Q1 EPS $1.48-$1.58, consensus $1.61
02/03/22
Check Point reports Q4 EPS $2.25, consensus $2.12
10/28/21
Check Point sees FY21 EPS $6.81-$7.01, consensus $6.78
BLND Blend Labs
$5.68 /

-0.3 (-5.02%)

03/31/22
Blend Labs sees FY22 revenue $230M-$250M, consensus $344.65M
03/31/22
Blend Labs sees Q1 revenue $63M-$66M, consensus $76.17M
03/31/22
Blend Labs reports Q4 EPS (32c), consensus (19c)
11/10/21
Blend Labs raises FY21 pro forma revenue view to $376M-$386M, consensus $369.75M
  • 02
    Nov
  • 04
    Aug
  • 30
    Jul
  • 16
    Jul
  • 16
    Jun
  • 09
    Apr
WYNN Wynn Resorts
$79.77 /

-1.34 (-1.65%)

03/14/22
Macau imposes more quarantine rules, GGR Asia reports
03/01/22
MLB cancels open day as MLBPA rejects offer, AP reports
02/17/22
Hard Rock finds at least three potential sites for NYC casino, AP reports
01/25/22
NFL Divisional Round averages 38.2M viewers, ESPN reports
PARA Paramount
$37.80 /

-0.315 (-0.83%)

03/30/22
Hulu loses Paramount, MGM films as EPIX deal ends, The Streamable says
02/28/22
Discovery plans to name Chris Licht to lead CNN, WSJ reports
02/25/22
Paramount working on Beyblade film with Jerry Bruckheimer, Deadline says
DELL Dell Technologies
$50.18 /

-4.1 (-7.55%)

01/01/22
Amazon looks particularly attractive after wild year for tech, Barron's says
10/24/21
HP stock looks like 'a screaming buy,' Barron's says
10/16/21
Spinoff could unlock value in Dell stock, Barron's says
CHKP Check Point
$138.42 /

+0.04 (+0.03%)

03/14/22
Israeli government sites crash in cyberattack, Haaretz reports
WYNN Wynn Resorts
$79.77 /

-1.34 (-1.65%)

03/25/22
Bet On It: Sports betting stocks remain under pressure despite NCAA tournament
03/18/22
Bet On It: Penn National-Barstool deal garners regulatory spotlight
03/14/22
What You Missed On Wall Street On Monday
03/14/22
What You Missed On Wall Street This Morning
W Wayfair
$110.75 /

-10.75 (-8.85%)

03/30/22
What You Missed On Wall Street On Wednesday
03/30/22
What You Missed On Wall Street This Morning
03/30/22
Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
03/30/22
Fly Intel: Pre-market Movers
UPST Upstart
$109.00 /

-4.87 (-4.28%)

03/22/22
What You Missed On Wall Street On Tuesday
03/22/22
What You Missed On Wall Street This Morning
03/22/22
Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
02/17/22
What You Missed On Wall Street On Thursday
TELL Tellurian
$5.30 /

-0.14 (-2.57%)

10/25/21
Wall Street in Fives - Must Read Lists for Monday
10/25/21
Wall Street in Fives - Must Read Lists at Midday
POSH Poshmark
$12.65 /

-0.69 (-5.17%)

03/23/22
What You Missed On Wall Street On Wednesday
03/23/22
What You Missed On Wall Street This Morning
03/23/22
Fly Intel: Pre-market Movers
03/22/22
Fly Intel: After-Hours Movers
PARA Paramount
$37.80 /

-0.315 (-0.83%)

02/16/22
What You Missed On Wall Street On Wednesday
02/16/22
What You Missed On Wall Street This Morning
GPS Gap
$14.08 /

-0.56 (-3.83%)

03/04/22
What You Missed On Wall Street On Friday
03/04/22
What You Missed On Wall Street This Morning
03/04/22
Fly Intel: Pre-market Movers
03/03/22
Fly Intel: After-Hours Movers
DELL Dell Technologies
$50.18 /

-4.1 (-7.55%)

03/31/22
What You Missed On Wall Street On Thursday
03/31/22
What You Missed On Wall Street This Morning
03/31/22
Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
03/08/22
What You Missed On Wall Street On Tuesday
CMA Comerica
$90.42 /

-2.455 (-2.64%)

01/19/22
Wall Street in Fives - Must Read Lists for Wednesday
01/19/22
Wall Street in Fives - Must Read Lists at Midday
CHKP Check Point
$138.42 /

+0.04 (+0.03%)

03/21/22
What You Missed On Wall Street On Monday
03/21/22
What You Missed On Wall Street This Morning
01/14/22
Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
BLND Blend Labs
$5.68 /

-0.3 (-5.02%)

03/31/22
Fly Intel: After-Hours Movers
03/21/22
Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
AWKNF Awakn Life Sciences
$1.20 /

+ (+0.00%)

03/03/22
Rising High: Exclusive talk with psychedelic biotech company Awakn
02/03/22
Rising High: Verano Holdings to buy Goodness Growth in $413M transaction
10/21/21
Rising High: Exclusive talk with psychedelic biotech company Awakn
04/20/22
Comerica - CMA
05/26/22
Dell Technologies - DELL
04/26/22
Comerica Inc.
05/05/22
Wynn Resorts Ltd.
05/10/22
Gap Inc.
WYNN Wynn Resorts
$79.77 /

-1.34 (-1.65%)

03/16/22
Early notable gainers among liquid option names on March 16th
03/02/22
Early notable gainers among liquid option names on March 2nd
01/25/22
Wynn Resorts call volume above normal and directionally bullish
01/18/22
Wynn Resorts call volume above normal and directionally bullish
W Wayfair
$110.75 /

-10.75 (-8.85%)

03/25/22
Wayfair put volume heavy and directionally bearish
02/16/22
Wayfair put volume heavy and directionally bearish
02/03/22
Wayfair put volume heavy and directionally bearish
01/20/22
Wayfair put volume heavy and directionally bearish
UPST Upstart
$109.00 /

-4.87 (-4.28%)

03/29/22
Upstart Holdings call volume above normal and directionally bullish
03/10/22
Cboe open-close data indicates $670k put block in Upstart Holdings is
02/18/22
Largest borrow rate increases among liquid names
02/17/22
Unusually active option classes on open February 17th
TELL Tellurian
$5.30 /

-0.14 (-2.57%)

03/25/22
Tellurian call volume above normal and directionally bullish
02/28/22
Unusually active option classes on open February 28th
02/22/22
Unusually active option classes on open February 22nd
01/11/22
Unusually active option classes on open January 11th
POSH Poshmark
$12.65 /

-0.69 (-5.17%)

03/22/22
Poshmark options imply 17.0% move in share price post-earnings
11/09/21
Poshmark options imply 16.7% move in share price post-earnings
PARA Paramount
$37.80 /

-0.315 (-0.83%)

03/14/22
Paramount Global call volume above normal and directionally bullish
03/14/22
Early notable gainers among liquid option names on March 14th
03/01/22
Paramount Global call volume above normal and directionally bullish
02/18/22
Notable open interest changes for February 18th
GPS Gap
$14.08 /

-0.56 (-3.83%)

03/23/22
Gap put volume heavy and directionally bearish
03/03/22
Gap options imply 11.5% move in share price post-earnings
02/11/22
Gap put volume heavy and directionally bearish
02/02/22
Gap put volume heavy and directionally bearish
DELL Dell Technologies
$50.18 /

-4.1 (-7.55%)

11/23/21
Dell Technologies options imply 4.8% move in share price post-earnings
11/22/21
Unusually active option classes on open November 22nd
11/03/21
Notable open interest changes for November 3rd
11/03/21
Thirteen new option listings on November 3rd
CMA Comerica
$90.42 /

-2.455 (-2.64%)

10/20/21
Early notable gainers among liquid option names on October 20th
BLND Blend Labs
$5.68 /

-0.3 (-5.02%)

03/21/22
Largest borrow rate increases among liquid names
10/19/21
Three new option listings and eight option delistings on October 19th
Downgrade
Silverback Therapeutics downgraded to Market Perform from Outperform at SVB Leerink » 08:56
04/01/22
04/01
08:56
04/01/22
08:56
SBTX

Silverback Therapeutics

$3.46 /

-0.065 (-1.85%)

SVB Leerink analyst Daina…

SVB Leerink analyst Daina Graybosch downgraded Silverback Therapeutics to Market Perform from Outperform with a price target of $1.80, down from $25.00. The downgrade follows the company's decision to discontinue their two leading oncology programs, SBT6050 and SBT6290, given toxicity that limited SBT6050 dose in combination with pembrolizumab and lack of SBT6050 single-agent activity, Graybosch tells investors in a research note.

ShowHide Related Items >><<
SBTX Silverback Therapeutics
$3.46 /

-0.065 (-1.85%)

04/01/22 JonesTrading
Silverback Therapeutics downgraded to Hold from Buy at JonesTrading
04/01/22 SVB Leerink
Silverback Therapeutics downgraded to Market Perform from Outperform at SVB Leerink
04/01/22 H.C. Wainwright
Silverback Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
04/01/22 Stifel
Silverback Therapeutics downgraded to Hold from Buy at Stifel
SBTX Silverback Therapeutics
$3.46 /

-0.065 (-1.85%)

03/31/22
Silverback Therapeutics reports FY21 EPS ($2.56), consensus ($2.60)
11/10/21
Silverback Therapeutics reports Q3 EPS (65c), consensus (67c)
Downgrade
Silverback Therapeutics downgraded to Hold from Buy at JonesTrading » 08:39
04/01/22
04/01
08:39
04/01/22
08:39
SBTX

Silverback Therapeutics

$3.46 /

-0.065 (-1.85%)

JonesTrading analyst…

JonesTrading analyst Soumit Roy downgraded Silverback Therapeutics to Hold from Buy with no price target after the company discontinued development of all of their oncology assets, including lead asset SBT6050, and shifted focus entirely to preclinical asset SBT8230 for chronic HBV. He sees a Hold rating as appropriate until there is more clarity on the path forward and Silverback is closer to clinical data, Roy tells investors.

ShowHide Related Items >><<
SBTX Silverback Therapeutics
$3.46 /

-0.065 (-1.85%)

04/01/22 SVB Leerink
Silverback Therapeutics downgraded to Market Perform from Outperform at SVB Leerink
04/01/22 H.C. Wainwright
Silverback Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
04/01/22 Stifel
Silverback Therapeutics downgraded to Hold from Buy at Stifel
07/07/21 H.C. Wainwright
Silverback strikes pact with Regeneron for Libtayo, says H.C. Wainwright
SBTX Silverback Therapeutics
$3.46 /

-0.065 (-1.85%)

03/31/22
Silverback Therapeutics reports FY21 EPS ($2.56), consensus ($2.60)
11/10/21
Silverback Therapeutics reports Q3 EPS (65c), consensus (67c)
Downgrade
Silverback Therapeutics downgraded to Market Perform from Outperform at SVB Leerink » 07:55
04/01/22
04/01
07:55
04/01/22
07:55
SBTX

Silverback Therapeutics

$3.46 /

-0.065 (-1.85%)

SVB Leerink analyst Daina…

SVB Leerink analyst Daina Graybosch downgraded Silverback Therapeutics to Market Perform from Outperform with a $1.80 price target.

ShowHide Related Items >><<
SBTX Silverback Therapeutics
$3.46 /

-0.065 (-1.85%)

04/01/22 H.C. Wainwright
Silverback Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
04/01/22 Stifel
Silverback Therapeutics downgraded to Hold from Buy at Stifel
07/07/21 H.C. Wainwright
Silverback strikes pact with Regeneron for Libtayo, says H.C. Wainwright
05/27/21
Fly Intel: Top five analyst initiations
SBTX Silverback Therapeutics
$3.46 /

-0.065 (-1.85%)

03/31/22
Silverback Therapeutics reports FY21 EPS ($2.56), consensus ($2.60)
11/10/21
Silverback Therapeutics reports Q3 EPS (65c), consensus (67c)
Downgrade
Silverback Therapeutics downgraded to Neutral from Buy at H.C. Wainwright » 06:06
04/01/22
04/01
06:06
04/01/22
06:06
SBTX

Silverback Therapeutics

$3.46 /

-0.065 (-1.85%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Edward White downgraded Silverback Therapeutics to Neutral from Buy without a price target. The company announced it has discontinued the development of SBT6050, its lead product candidate comprised of a TLR8 linker-payload conjugated to a HER2-directed monoclonal antibody targeting Nectin4, White tells investors in a research note. The company has also decided to discontinue the development of SBT6290 due to the likelihood of it having a similar clinical profile to SBT6050, he adds. White cites these moves for the downgrade.

ShowHide Related Items >><<
SBTX Silverback Therapeutics
$3.46 /

-0.065 (-1.85%)

04/01/22 Stifel
Silverback Therapeutics downgraded to Hold from Buy at Stifel
07/07/21 H.C. Wainwright
Silverback strikes pact with Regeneron for Libtayo, says H.C. Wainwright
05/27/21
Fly Intel: Top five analyst initiations
05/27/21 JonesTrading
Silverback Therapeutics initiated with a Buy at JonesTrading
SBTX Silverback Therapeutics
$3.46 /

-0.065 (-1.85%)

03/31/22
Silverback Therapeutics reports FY21 EPS ($2.56), consensus ($2.60)
11/10/21
Silverback Therapeutics reports Q3 EPS (65c), consensus (67c)
Downgrade
Silverback Therapeutics downgraded to Hold from Buy at Stifel » 05:25
04/01/22
04/01
05:25
04/01/22
05:25
SBTX

Silverback Therapeutics

$3.46 /

-0.065 (-1.85%)

Stifel analyst Stephen…

Stifel analyst Stephen Willey downgraded Silverback Therapeutics to Hold from Buy with a price target of $6, down from $32. Management's discontinuation of the SBT6050/SBT6290 development programs, a decision predicated on limited single-agent SBT6050 anti-tumor activity observed to date and cytokine-related, dose-limiting toxicities which challenge the pursuit of combinations, "represents a material change" to the investment thesis, Willey tells investors in a research note. The analyst believes SBT8230 still holds promise in hepatitis B virus but says additional visibility into the potential for this asset "will take significant time to manifest."

ShowHide Related Items >><<
SBTX Silverback Therapeutics
$3.46 /

-0.065 (-1.85%)

07/07/21 H.C. Wainwright
Silverback strikes pact with Regeneron for Libtayo, says H.C. Wainwright
05/27/21
Fly Intel: Top five analyst initiations
05/27/21 JonesTrading
Silverback Therapeutics initiated with a Buy at JonesTrading
SBTX Silverback Therapeutics
$3.46 /

-0.065 (-1.85%)

03/31/22
Silverback Therapeutics reports FY21 EPS ($2.56), consensus ($2.60)
11/10/21
Silverback Therapeutics reports Q3 EPS (65c), consensus (67c)
Earnings
Silverback Therapeutics reports FY21 EPS ($2.56), consensus ($2.60) » 16:01
03/31/22
03/31
16:01
03/31/22
16:01
SBTX

Silverback Therapeutics

$3.42 /

-0.1 (-2.84%)

"Upon comprehensive…

"Upon comprehensive review of our clinical and preclinical data for our TLR8 oncology programs, we have made the decision to discontinue the development of SBT6050 and SBT6290, and focus our resources on SBT8230 for chronic HBV as well as our ImmunoTAC discovery programs," said Laura Shawver, Ph.D., chief executive officer of Silverback. "We would like to thank the investigators and the staff at each of our sites, and most importantly, the patients who participated in our trial and their families."

ShowHide Related Items >><<
SBTX Silverback Therapeutics
$3.42 /

-0.1 (-2.84%)

07/07/21 H.C. Wainwright
Silverback strikes pact with Regeneron for Libtayo, says H.C. Wainwright
05/27/21
Fly Intel: Top five analyst initiations
05/27/21 JonesTrading
Silverback Therapeutics initiated with a Buy at JonesTrading
SBTX Silverback Therapeutics
$3.42 /

-0.1 (-2.84%)

11/10/21
Silverback Therapeutics reports Q3 EPS (65c), consensus (67c)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.